1. Home
  2. ADAG vs SSP Comparison

ADAG vs SSP Comparison

Compare ADAG & SSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$4.47

Market Cap

260.3M

Sector

Health Care

ML Signal

HOLD

Logo E.W. Scripps Company (The)

SSP

E.W. Scripps Company (The)

HOLD

Current Price

$3.13

Market Cap

264.6M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADAG
SSP
Founded
2011
1878
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Broadcasting
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
260.3M
264.6M
IPO Year
2020
1998

Fundamental Metrics

Financial Performance
Metric
ADAG
SSP
Price
$4.47
$3.13
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$8.25
$6.95
AVG Volume (30 Days)
270.7K
827.2K
Earning Date
04-01-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,150,585,000.00
Revenue This Year
N/A
$8.34
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.44
$2.04
52 Week High
$4.85
$5.39

Technical Indicators

Market Signals
Indicator
ADAG
SSP
Relative Strength Index (RSI) 62.38 49.83
Support Level $3.21 $2.09
Resistance Level $4.66 $3.75
Average True Range (ATR) 0.45 0.19
MACD 0.09 0.06
Stochastic Oscillator 75.46 82.73

Price Performance

Historical Comparison
ADAG
SSP

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

Share on Social Networks: